With FDA nod for Lumryz, Avadel is set to Jazz up the narcolepsy market

Waking up in the middle of the night to take a pill is the onerous way patients take the world’s top-selling narcolepsy drug, Jazz Pharmaceuticals’ Xyrem.

But there finally is relief from that challenging regimen as the FDA has blessed a longer-acting, once-at-bedtime treatment. Avadel Pharmaceuticals’ Lumryz is a different formulation of the same drug (sodium oxybate) Jazz has used for its treatment for more than two decades.